Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 8%, reaching HKD 11.57 with a trading volume of HKD 23.73 million, following the announcement of significant clinical trial results for its weight loss drug ASC47 combined with semaglutide [1] Group 1: Clinical Trial Results - Gilead announced that in a study conducted on obese participants (BMI ≥ 30 kg/m²), the combination of ASC47 and semaglutide showed a weight loss effect that was 56.2% greater compared to the placebo combined with semaglutide [1] Group 2: Future Research Implications - The CEO of Gilead, Wu Jinzi, stated that this research provides important concept validation data, which will serve as a critical basis for the design of subsequent Phase IIb combination therapy studies targeting various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 8%, reaching HKD 11.57, with a trading volume of HKD 23.73 million, following the announcement of significant weight loss results from its candidate drug ASC47 in combination with semaglutide [1] Group 1: Company Announcement - Gilead Sciences announced that, on day 29, the weight loss effect of ASC47 combined with semaglutide in obese subjects (BMI ≥ 30 kg/m²) was enhanced by up to 56.2% compared to the placebo combined with semaglutide [1] - The founder, chairman, and CEO of Gilead Sciences, Wu Jinzi, stated that this study provides important proof-of-concept data, which will serve as a critical basis for the design of subsequent Phase IIb combination therapy studies for various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

Core Viewpoint - Novo Nordisk's Wegovy has received FDA approval for a new indication to treat metabolic associated fatty liver disease (MASH) with moderate to severe liver fibrosis in non-cirrhotic adult patients, marking it as the first and only GLP-1 drug approved for this condition [1] Group 1 - Novo Nordisk's stock rose nearly 3% to $55.33 following the FDA approval announcement [1] - The approval is based on a supplemental new drug application (sNDA) for Wegovy (semaglutide 2.4mg) [1] - The new indication is intended for use alongside dietary control and increased physical activity [1] Group 2 - Martin Holst Lange, the company's Executive Vice President and Chief Scientific Officer, emphasized Wegovy's unique position in the market as the first GLP-1 drug approved for MASH treatment [1]